Immunotherapy drug helps patients go cancer-free for twice as long, trial shows
An immunotherapy drug could help some cancer patients live years longer without the disease getting worse or coming back, a trial has found.
Pembrolizumab, sold under the brand name Keytruda, kept head and neck cancers at bay for five years compared to 30 months with standard care.
It also slashed the risk of the disease returning in another part of the body, the study suggests.
Head and neck cancer refers to a group of cancers that can develop anywhere in the head or neck, including the mouth, the oesophagus, the space behind the nose, the salivary gland, or the voice box.
Standard care, which includes surgery to remove tumours followed by radiotherapy with or without chemotherapy, has not changed for these patients in more than two decades, according to researchers.
The global Keynote-689 trial was carried out at 192 sites in 24 countries, and involved 714 patients.
Some 363 people received pembrolizumab followed by standard care, with the remainder receiving standard care only.
Pembrolizumab works by targeting a protein known as PD-L1, which is found on T cells and helps the immune system recognise and fight cancer.
By blocking this protein, the treatment helps the immune system fight cancer more effectively.
The treatment is already approved for use on its own or in combination with chemotherapy for patients with a certain type of head and neck cancer that has come back or spread around the body.
The trial, which is being presented at the American Society of Clinical Oncology (Asco) annual meeting, found cancer returned in half the patients given pembrolizumab after five years, compared with two-and-a-half years in those receiving standard care.
After three years, the risk of cancer returning somewhere else in the body was also 10% lower among those on pembrolizumab.
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research, London, and consultant oncologist at the Royal Marsden NHS Foundation Trust, said: 'For patients with newly-diagnosed, locally-advanced head and neck cancer, treatments haven't changed in over two decades.
'Immunotherapy has been amazingly beneficial for patients with cancer that has come back or spread around the body but, until now, it hasn't been as successful for those presenting for the first time with disease which has spread to nearby areas.
'This research shows that immunotherapy could change the world for these patients – it significantly decreases the chance of cancer spreading around the body, at which point it's incredibly difficult to treat.'
Prof Harrington added that the drug 'dramatically increases the duration of disease remission – for years longer than the current standard treatments'.
'It works particularly well for those with high levels of immune markers, but it's really exciting to see that the treatment improves outcomes for all head and neck cancer patients, regardless of these levels,' he said.
It is estimated there are about 12,800 cases of head and neck cancer in the UK each year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
4 hours ago
- Daily Mail
Sleep problem that affects 10million could trigger deadliest cancer - first major study to spot the link
Severe snorers may be at higher risk of one of Britain's deadliest cancer, shock new research has suggested. It is already known that patients with obstructive sleep apnoea (OSA), which often causes problem snoring, may be more likely to develop cancer. Now, one of the world's first trials exploring the condition and lung cancer specifically has found a 'significant' link between the two. US researchers, who assessed the health records of more than 2.4million adults, said they cannot be sure exactly why the common sleep disorder raises this risk. But they believe it may be due to the lack of oxygen people get during the night - or lifestyle factors including smoking and even obesity. Presenting the findings at the American Society of Clinical Oncology conference in Chicago, scientists urged policymakers to consider screening those with the condition for the disease and tackle sleep apnea early, soon after a diagnosis. OSA, which impacts nearly a billion people worldwide, causes the walls of the throat to relax and narrow or close for a few seconds during sleep. This triggers breathing pauses and loud snoring. Up to 3.9 million people in the UK are estimated to have moderate or severe OSA, although it is considered to be under-diagnosed affecting up to 10million. Not all snorers have sleep apnoea, but the two often go hand in hand, and the louder the snoring, the greater the chances of having it. In the study, researchers at Marshall University in West Virginia, tracked lung cancer diagnoses separating those diagnosed with OSA and those without. After accounting for factors that could skew the results, such as age and other diagnosed health conditions, they found OSA patients were 1.21 times more likely to develop lung cancer compared to those without OSA. Dr Jowan Al-Nusair, study co-author and physician at Marshall University told MailOnline it was 'one of the first statistically significant studies' to prove a link between the condition and lung cancer. 'While further studies are definitely now needed to investigate just how the significant the link truly is, this suggests OSA may be a preventable risk factor for lung cancer. 'We should be more closely monitoring patients with OSA. Patients would definitely benefit from screening and early intervention to combat OSA. 'Additional studies are essential to understand exactly why OSA may increase this risk. 'We really hope this will pave the way for future research and testing.' Lung cancer strikes around 50,000 people in the UK and 230,000 in the US every year. It is the world's biggest cancer killer. It is notoriously difficult to diagnose and often appears later when it's harder to treat. Figures show it kills four out of five patients within five years. Fewer than 10 per cent of people survive their disease for a decade or more. Despite the progress, a disparity among sexes is emerging, with women between the ages of 35 and 54 being diagnosed with lung cancer at higher rates than men in that same age group. Science has long established that smoking definitively causes lung cancer and is the primary risk factor for the disease. But lung cancer rates, which have been dropping for decades as the world weans off tobacco, are also now rising in young, otherwise healthy people who've never smoked. Experts told MailOnline the disease should not be viewed as 'an old person's disease' — as it was previously seen. Speaking at ASCO it was also suggested diet, changes in exercise habits and changes in work patterns could play a part in this increased risk. It comes as a study by The Sleep Charity last year found nine in ten people experience some sort of sleep problem. Poor sleep has been linked to a number of health problems, including cancer, stroke and infertility. Experts have long advised that waking up during the night does not necessarily mean you have insomnia, which figures suggest affects up to 14million Brits. Still, sleep deprivation takes its own toll, from irritability and reduced focus in the short term, to an increased risk of obesity, heart disease and diabetes.
Daily Mail
6 hours ago
- Daily Mail
Experts reveal what's driving explosion in under 50s cancer cases - as landmark study shows 23 per cent surge since the 90s
Cancer deaths have fallen by more than a fifth over the past 50 years—but diagnoses have soared with cases in younger adults driving the trend, a landmark study reveals. Experts say the spike in diagnoses is being fuelled in part by lifestyle factors—including smoking, obesity and poor diet—which remain among the leading causes. The analysis, from Cancer Research UK, is the first to examine 50 years of NHS cancer data, revealing striking progress—but also alarming new trends. The data reveals that although survival rates have improved dramatically since the 1970s, the risk of developing cancer has risen just as sharply. In 1973, around 328 in every 100,000 people died from the disease. By 2023, that figure had fallen to 252—a 22 per cent drop—thanks to earlier diagnosis and better treatments. But over the same period, the number of people developing cancer has soared by almost 50 per cent. Incidence rates have climbed from 413 to 607 per 100,000 people, with some of the sharpest rises seen in under 50s. Among those aged 20 to 49, rates are up by 23 per cent since the early 1990s. Scientists are still trying to explore the factors behind the rise in early onset cancers, with some suggesting modern diets and exposure to substances like microplastics, or a combination of several triggers, could be to blame. Speaking this week at the American Society of Clinical Oncology conference in Chicago —the world's biggest cancer conference—experts also cautioned that poor lifestyle was likely the driving factor. Presenting research on the key factors influencing the surge in colon cancer cases among people in their 20s, 30s and 40s, Dr Jessica Paulus a senior director of research at Ontada, said obesity was far higher among early-onset patients than 'average age'. Of the 14,611 young patients tracked in the study, more than a third were obese at time of diagnosis. 'Interestingly, distress thermometer data also showed early-onset patients were more likely to report high or moderate distress' at time of diagnosis compared to older patients, she added. This thermometer is a tool health professionals ask patients to use to self-report feelings or issues, such as financial concerns, pain, fatigue and worry. But drinking, physical inactivity and poor diet too plays a 'huge' role too, Professor Neil Iyengar, an expert in breast oncology and the impact of lifestyle factors on cancer at the Memorial Sloan Kettering Cancer Centre in New York, said. He told MailOnline: 'The link between obesity and several forms of cancer is already well-established, but this data is mostly from older people. 'Obesity rates are accelerating in young people. 'But having too much fat—even if you have a normal body weight or body mass index—also increases the risk of developing cancer. 'It's never too early to start good eating and exercise patterns. 'We need to start thinking of some foods and high-sugar beverages in a similar way that we think about smoking: unnecessary, addictive, and harmful.' Other experts, however, cautioned that tobacco was likely not behind the rise in younger cancer cases. Professor Paul Pharoah, an expert in cancer epidemiology at Cedars-Sinai Medical Centre in Los Angeles told MailOnline: 'Incidence of the one major smoking related cancer, lung cancer, has come down in all age groups in men. 'In women, lung cancer incidence has fallen in younger women since 1990, but continues to increase in older women.' He added: 'Screening is also unlikely to be a cause of the difference between younger and older people, as the screening programmes implemented by the NHS since 1990 would be more likely to increase incidence in older individuals.' While cancer survival in England and Wales has doubled since the 1970s, progress has slowed sharply over the past decade. The report found that survival improved three to five times faster in earlier decades than it has since 2010. And despite the gains, the UK continues to lag behind comparable countries on key cancer outcomes. Late diagnosis remains a major issue. Only 54 per cent of cancers in England are diagnosed at stage one or two—the earliest phases, when tumours are usually small, haven't spread far, and are most treatable. That figure has barely improved in the last ten years. Cancer Research UK's chief executive, Michelle Mitchell, said: 'It's fantastic to see that thanks to research, cancer death rates have drastically reduced and survival has doubled. 'But more than 460 people are still dying from cancer every day in the UK. Too many cases are still being diagnosed too late.' The report also highlights the leading preventable causes of cancer. Smoking remains the biggest risk factor, but obesity—now linked to 13 different types of the disease—is rising rapidly. Other contributors include drinking, poor diet, sunbeds, lack of exercise and failure to protect skin from the sun. Cancer Research UK is urging the Government to act swiftly and decisively in its upcoming National Cancer Plan for England. It is calling for earlier diagnosis, faster access to tests, better GP referrals and a national lung cancer screening programme—arguing that these steps could save thousands of lives. Mitchell added: 'If this plan is done right, it could transform cancer care in this country and ensure people affected by cancer live longer, better lives.'
The Independent
7 hours ago
- The Independent
Eating this kind of bread can raise colon cancer patients' risk of death
Eating white bread and other foods considered to be proinflammatory can raise colon cancer patients' risk of death from the disease, researchers said this week. Of a study of more than 1,600 patients with stage III colon cancer, people who consumed the most of those foods — also including french fries, hot dogs, and soda — during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet. The patients who ate a proinflammatory diet had an 87 percent higher risk of death than those who consumed the least proinflammatory food. Inflammation is the body's immune response to stimulus, such as falling down or burning your finger. Both too little and too much inflammation can cause problems, and most chronic diseases are believed to be rooted in inflammation that lasts over time. Some of the foods that can contribute to inflammation have been linked to cancer risk. 'One of the most common questions that patients ask is what they should do after treatment to maximally reduce their risk of cancer recurrence and improve survival,' Dr. Sara Char, a clinical fellow in hematology and oncology at Boston's Dana-Farber Cancer Institute, said in a statement. 'These findings add to the published literature about the importance of dietary patterns and physical activity in outcomes of patients with colorectal cancer.' Char was the first author of the research which was presented on Sunday at this year's American Society of Clinical Oncology Annual Meeting. 'This study provides additional evidence that diet may be important for improving outcomes and survival in patients with stage III colon cancer,' co-author Dr. Kimmie Ng, also of Dana-Farber, said. 'Further studies are needed to tailor specific dietary recommendations for patients with colon cancer, and to understand the biological mechanisms underlying the relationship between proinflammatory diets and survival.' The use of the anti-inflammatory drug in the participants' trial, which is known as celecoxib, did not have a significant influence on the relationship between diet and survival, but the authors also noted that those who engaged in higher levels of physical activity had the best overall survival outcomes. Their findings come following previous research that showed systemic inflammation can increase the risk of colon cancer development and progression. Using anti-inflammatory drugs can reduce the risk of recurrence in selected patients with stage III colon cancer, the Dana-Farber researchers said. It remains unclear how much diet could affect cancer outcomes after treatment, but these findings add to a growing body of knowledge that could affect tens of thousands of Americans with colorectal cancer. Some 150,000 people are diagnosed with colorectal cancer each year in the U.S. It is the second-most common cause of cancer deaths for men and women in the U.S., and is expected to cause about 52,900 deaths this year. The average five-year survival for patients with stage III colon cancer is around 80 percent, although between 25 and 35 percent of patients experience a recurrence of cancer during that time. The researchers say that they plan to conduct more detailed investigations of the biological effects of diet and lifestyle on colon cancer outcomes, including those with metastatic colon cancer and those diagnosed at younger ages, under age 50. The majority of Americans — as many as 57 percent — may be eating a diet that promotes inflammation, researchers at the Ohio State University found last year. In 2018, a Harvard study found that people who ate foods that promoted inflammation had a higher rate of colorectal cancer compared with people who ate the least foods, with a 22 percent higher risk for men than women. Eating white bread and drinking alcohol are linked to an increased risk for developing colorectal cancer. Whole grains have anti-cancer properties and eating fiber helps to reduce colorectal cancer risk, researchers told Fox News Digital in 2023. The next year, a study found potential risk for white bread intake. Alternatively, consuming more dark leafy greens, vegetables, nuts, whole grains, and protein sources that are high in omega-3 fatty acids can help fight inflammation, according to UCLA Health. The Mediterranean diet may be the most beneficial, Johns Hopkins Medicine notes. 'I want to emphasize that people really need to focus on their pattern of eating — as opposed to eating a few particular foods — to reduce inflammation,' Dr. Edwin McDonald, a gastroenterologist at UChicago Medicine, wrote. ' There's no miracle food out there that's going to cure people with chronic inflammation. You need to have an anti-inflammatory lifestyle and diet.'
